Table 2 Use of renin-angiotensin system inhibitors and incidence of fracture
Variables | Fracture case | Controls | Conditional logistic regression | ||||
|---|---|---|---|---|---|---|---|
(n = 1,049) | (n = 1,049) | ||||||
n | % | n | % | OR (95% CI) | P-value | ||
RASi use | Never-user | 819 | 51.3 | 778 | 48.7 | ||
Ever-user | 230 | 45.9 | 271 | 54.1 | 0.73 (0.59–0.91) | 0.004 | |
RASi prescription at the index date | Never-user | 819 | 51.3 | 778 | 48.7 | ||
Past user | 67 | 46.5 | 77 | 53.5 | 0.72 (0.49–1.05) | 0.084 | |
Current user | 163 | 45.7 | 194 | 54.3 | 0.73 (0.57–0.94) | 0.014 | |
RASi cumulative dose (cDDD) | 0 < cDDD < 90 | 44 | 40.0 | 66 | 60.0 | 0.65 (0.43–0.99) | 0.043 |
90 ≤ cDDD < 180 | 26 | 36.6 | 45 | 63.4 | 0.53 (0.31–0.90) | 0.018 | |
180 ≤ cDDD < 365 | 28 | 37.3 | 47 | 62.7 | 0.47 (0.27–0.82) | 0.007 | |
cDDD ≥ 365 | 132 | 53.9 | 113 | 46.1 | 0.94 (0.70–1.26) | 0.693 | |
Cumulative prescription days | 0 < days < 90 | 43 | 37.7 | 71 | 62.3 | 0.60 (0.39–0.90) | 0.014 |
90 ≤ days < 180 | 30 | 41.7 | 42 | 58.3 | 0.61 (0.37–1.03) | 0.063 | |
180 ≤ days < 365 | 27 | 35.5 | 49 | 64.5 | 0.49 (0.29–0.83) | 0.009 | |
Days ≥ 365 | 130 | 54.4 | 109 | 45.6 | 0.95 (0.71–1.28) | 0.744 | |
Mean prescribed daily dose (PDD) | PDD < 0.5 | 7 | 46.7 | 8 | 53.3 | 0.84 (0.29–2.47) | 0.752 |
0.5 ≤ PDD < 1 | 167 | 44.5 | 208 | 55.5 | 0.72 (0.56–0.92) | 0.008 | |
PDD ≥ 1 | 56 | 50.5 | 55 | 49.5 | 0.75 (0.49–1.15) | 0.194 | |